Clinical trial
Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell…
NCT00243204 · Point Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00243204 |
|---|---|
| Title | Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy |
| Lead sponsor | Point Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small Cell Lung |
| Intervention type | Drug |
| Interventions | talabostat mesylate, docetaxel |
| Enrollment | 400 |
| Start date | Jan 1, 2006 |
| First posted | Oct 21, 2005 |
| Last update posted | Jun 8, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: